https://www.selleckchem.com/pr....oducts/Everolimus(RA
05) , while patients in group A had higher WBC count, blasts in peripheral blood, minimal residual disease (MRD) in bone marrow. The CR(1) rates of group A, B, C, and D were 50.0%、32.4%、59.8%、39.0% respectively (P=0.003) , and the relapse rates were 55.6%, 50.0%, 21.1%, 40.0% (P less then 0.001) . As to survival, the median OS in each group was 6.25, 3.0, 15.5, 10.5 months respectively (P less then 0.001) , and the median PFS was 5.0, 4.0, 10.0, 6.7 months (P=0.032) . Conclusion Adult AML patients with FLT3-ITD and CEBPAdm co
Like
Comment
Share
